Siewert-Delle A, Ljungman S, Hartford M, Wikstrand J
Department of Nephrology, Sahlgrenska University Hospital, University of Gothenburg, Sweden.
Am J Hypertens. 1995 Feb;8(2):113-23. doi: 10.1016/0895-7061(94)00174-A.
The effect of intensified blood pressure (BP) control with a reduction of the diastolic BP to < or = 85 mm Hg on renal function and urinary albumin excretion (UAE) was studied in 28 men with primary hypertension (aged 62 to 72 years) treated for 13 +/- 5 years with beta-blockade, diuretics, or hydralazine. They were compared with 25 normotensive (NT) men of similar age. At baseline (BL), glomerular filtration rate (GFR), renal plasma flow (RPF) (clearance of inulin and para-aminohippurate), and the UAE were studied. Thereafter, all antihypertensive drugs except beta-blockers were withdrawn and either felodipine (5 to 20 mg; n = 13) or ramipril (2.5 to 10 mg; n = 15) was added in a double blind, randomized fashion. Hydrochlorothiazide was added if necessary. The investigations were repeated after 6 weeks and 1 year of double-blind treatment. At BL, the BP and the renal vascular resistance (RVR) were significantly higher and GFR and RPF were significantly lower in both hypertensive groups than in NT. After 1 year, the BP treatment goal was reached by all patients in the felodipine group but only by two-thirds in the ramipril group in spite of addition of diuretics to 60% of the latter group. In the felodipine group, the BP, GFR, and RVR after 1 year no longer differed significantly from normal. The UAE and the fractional albumin clearance increased significantly after 1 year's treatment in the felodipine group but did not change in the ramipril group. The fractional albumin clearance, however, did not differ significantly from normal either at BL or after 1 year's treatment in any of the hypertensive groups. It is therefore possible to reduce BP and improve renal function in primary hypertension to levels not significantly different from normal after treatment with felodipine in combination with beta-blockade. Although this regimen increased the low UAE slightly, the fractional albumin clearance changed less and did not differ significantly from normal. The ramipril/beta-blocker combination reduced BP less and did not change the slightly reduced renal function or the UAE.
对28名原发性高血压男性患者(年龄62至72岁,接受β受体阻滞剂、利尿剂或肼屈嗪治疗13±5年)进行研究,探讨强化血压(BP)控制使舒张压降至≤85 mmHg对肾功能和尿白蛋白排泄(UAE)的影响。将他们与25名年龄相仿的血压正常(NT)男性进行比较。在基线(BL)时,研究肾小球滤过率(GFR)、肾血浆流量(RPF)(菊粉和对氨基马尿酸清除率)以及UAE。此后,停用除β受体阻滞剂以外的所有降压药物,并以双盲、随机方式添加非洛地平(5至20 mg;n = 13)或雷米普利(2.5至10 mg;n = 15)。必要时添加氢氯噻嗪。在双盲治疗6周和1年后重复进行检查。在BL时,两个高血压组的血压和肾血管阻力(RVR)均显著高于NT组,而GFR和RPF则显著低于NT组。1年后,非洛地平组所有患者均达到血压治疗目标,而雷米普利组尽管60%的患者加用了利尿剂,但只有三分之二的患者达到目标。在非洛地平组,1年后的血压、GFR和RVR与正常水平不再有显著差异。非洛地平组治疗1年后UAE和白蛋白清除分数显著增加,而雷米普利组未改变。然而,在任何高血压组中,白蛋白清除分数在BL时或治疗1年后与正常水平均无显著差异。因此,在原发性高血压患者中,联合β受体阻滞剂使用非洛地平治疗后,有可能将血压降低并使肾功能改善至与正常水平无显著差异。尽管该治疗方案使低UAE略有增加,但白蛋白清除分数变化较小且与正常水平无显著差异。雷米普利/β受体阻滞剂联合治疗降低血压的效果较差,且未改变略有降低的肾功能或UAE。